Study record

The Role of Mitochondria-Derived Peptides in Cardiovascular Diseases and Their Potential as Therapeutic Targets

Dabravolski SA, Nikiforov NG, Starodubova AV et al. · Int J Mol Sci · 2021

ReviewRelated mitochondrial peptideEvidence tier R
PubMed 34445477doi:10.3390/ijms22168770Full text (PMC)Compare with another study

What this study reported

Reviewed humanin, MOTS-c and SHLP1-6 and their reported anti-apoptotic, anti-inflammatory and antioxidant activities in cells and animals, and their relationship to cardiovascular risk factors including insulin resistance, hyperlipidaemia and ageing. Also discussed modified and synthetic peptides and the idea of mitochondria-derived peptides as biomarkers.

Limitations

Narrative review without systematic search; MOTS-c is covered alongside several peptides and most underlying evidence is preclinical.

Study record

Annotated fields for this study
Study modelReview
Substance studiedRelated mitochondrial peptideThe paper is mainly about another mitochondrial-derived peptide, such as humanin.
SpeciesNot reported
System studiedNarrative review of mitochondria-derived peptides and cardiovascular risk factors
PopulationNot reported
DesignNarrative review
Sample size as reportedNot reported
Control groupNot reported
Route (data field only)Not reported
Endpoints measuredapoptosis; inflammation; oxidative stress; insulin resistance; atherosclerosis
Pathways measuredApoptosis · Inflammation · Oxidative stress · Insulin & glucose handling
Research areasCardiovascular · Metabolic · Aging
Evidence tierR — Review (context, not evidence)
Publication typesJournal Article, Review

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Indirect
Model applicability
n/a
Sample size
n/a
Controls
n/a
Outcome validity
n/a
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.